OGN Latest Headlines

Organon: Hold Rating Maintained Amid Mixed Fundamentals, Governance Uncertainty, and Margin Pressures

at www.tipranks.com (Mon, 16-Feb 7:35 AM)

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Organon (OGN)

at www.tipranks.com (Sat, 14-Feb 9:00 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Maravai Lifesciences Holdings (MRVI) and Vertex Pharmaceuticals (VRTX)

at www.tipranks.com (Fri, 13-Feb 10:40 AM)

Organon Maintains Stable Revenue and Margin Guidance Amid Shifting Market Dynamics

Market Chameleon (Thu, 12-Feb 7:59 AM)

Organon Earnings Call Balances Stability With Rising Risks

at www.tipranks.com (Thu, 12-Feb 7:29 PM)

Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage

at seekingalpha.com (Thu, 12-Feb 10:45 AM)

Organon declares $0.02 dividend

at seekingalpha.com (Thu, 12-Feb 8:54 AM)

Organon falls as women’s health unit drives Q4 miss

at seekingalpha.com (Thu, 12-Feb 8:47 AM)

Organon Reports Soft Q4 2025 Results, Biosimilars Grow

at www.tipranks.com (Thu, 12-Feb 8:18 AM)

Organon in charts: Q4 revenue from Women’s Health and Established Brands down; Biosimilars up Y/Y

at seekingalpha.com (Thu, 12-Feb 7:59 AM)

Earnings Snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook

at seekingalpha.com (Thu, 12-Feb 7:52 AM)

Organon Non-GAAP EPS of $0.63 misses by $0.10, revenue of $1.51B in-line

at seekingalpha.com (Thu, 12-Feb 7:32 AM)

Organon Q4 Earnings Preview: Cautious view amid weak year

at seekingalpha.com (Wed, 11-Feb 11:17 AM)

FDA Extends NEXPLANON Implant Duration to 5 Years: OGN Advances Women’s Health With Broader Patient Inclusion

Market Chameleon (Tue, 20-Jan 11:45 AM)

Organon Gains Strategic Edge with FDA Approval of First PERJETA Biosimilar POHERDY

Market Chameleon (Mon, 17-Nov 8:41 AM)